Introduction
============

Cough is one of the most common respiratory symptoms encountered by clinicians \[[@B1]\], with the reported prevalence varying between 5% and 40% \[[@B2]-[@B4]\]. Cough is also one of the critical factors affecting the quality of life in patients with respiratory diseases. Cough management has massive economic consequences. The first guideline on the management of cough with a significant positive impact was championed in 1998 \[[@B5]\], followed by the publication of other guidelines on chronic cough \[[@B6]-[@B9]\]. The Chinese Medical Association published \"Diagnosis and treatment guide (draft) of cough\" in 2005 \[[@B10]\], and then the American College of Chest Physicians published evidence-based guidelines for diagnosis and treatment of acute cough, subacute cough, and chronic cough in adults and chronic cough in children in 2006 \[[@B1],[@B6],[@B11]\].

Over-the-counter combination cough medication such as cough syrup including traditional Chinese medicine is usually the first choice in China. The majority of people with cough who consulted a health care professional received the diagnosis and was informed that over the counter cough medications could relieve the symptoms. However, there are still a number of those with unclear diagnosis or failure to respond to therapy. The present study aimed at investigating clinical epidemiology of cough through a national study of two questionnaire surveys sent to primary care physicians in China. Approximately 18,000 subjects with daytime or night symptoms of cough and with diagnoses of respiratory disease were recruited for questionnaires from February 2005 to April 2006 as Survey 1 and from June 2007 to December 2007 as Survey 2. It provided further information about the demographic and symptomatic profile in the population and curative effects for cough in Chinese patients with respiratory diseases. This is one of the national projects organized by the Chinese Medical Doctor Association in order to obtain a better understanding of coughs while hoping the results could lead to new ideas and plans to explore in regard to molecular mechanisms and therapies.

Methods
=======

Patients
--------

The present study identified clinical characteristics of patients with cough from a nationwide-based survey conducted by the Chinese Medical Doctor Association. Subjects recruited had daytime or nighttime symptoms of cough and diagnoses of respiratory diseases, from 85 primary care medical centers. The 85 clinics are primary care centers chosen from the north and south of China as representatives in China. One survey started from February 2005 to April 2006 was named Survey 1 and one from June 2007 to December 2007 was named Survey 2. The two surveys were performed at the same 85 clinics. There was no overlap of the two surveys. The reason for calculating using two surveys was to see the improvement of health care and medical care inbetween the two time periods. Patients were provided with written information prior to obtaining oral consent. The study is a questionnaire survey aimed at investigating the clinical epidemiology of the cough for patients when first visiting the primary care center. Information on patient health care data, e.g. numbers, home address, phone number and others, was protected.

Evaluation Scores
-----------------

Physicians were invited to complete and follow up the cough questionnaires and were then completed by the referred patients who had been in primary care settings during the first time. After then, they were continuously followed up for an additional 14 days, in order to audit social and demographic factors as well as qualitative measures of responses to treatment. The physicians filled out the questionnaires. Sections of open questions were asked, including demographic details, symptoms, history of the cough, hypersusceptibility patterns, and treatment outcomes. Hypersusceptibility was defined as a cough condition of abnormal susceptibility to stimuli that are entirely innocuous in the normal individual. Cough severity was assessed on a scale of 0 (no cough) to 3(severe cough) and recorded on a daily record. Effectiveness was evaluated as cured (symptom score decreased to 0), markedly improved (symptom score decreased ≥ 4), improved (Symptom score decreased ≥ 2), or no effect (unchanged or aggravated). Adverse events were elicited at each visit by enquiring about the side effects of therapy recorded from a symptom checklist.

Statistics
----------

Data were analyzed by the two-sided test and p value less than 0.05 was considered significant. Non-parametric statistics rank sum test was used for the analysis of recovery percentage. The quota target was used and described by statisticians, including the computation arithmetic mean value, the standard deviation, the median, the minimum value, the maximum value. The example number was calculated and the percentage of corresponding was classified with the identification target. Data was analyzed using the SAS 9.1.2 program by Health Statistics Laboratory of Chinese Center for Disease Control and Prevention.

Results
=======

Of 18000 questionnaires, 8216 were received by the end of April, 2006, and 9711 by the end of Dec 2007, respectively. There were 4655 males and 3561 females with a mean age of 25.7 (standard deviation 24, range 1-98 years) in Survey 1 with 8216 patients. Of them, 46% were less than 10 years old (Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}). There were 5331 males and 4010 females with a mean age of 22.3 years (standard deviation 22 years) in Survey 2 with 9711 patients, among whom the age of 425 patients were not recorded.

###### 

Characteristic of the subjects in Survey 1

  Age     Male   Female   Total                  
  ------- ------ -------- ------- ------- ------ -------
  0-10    2102   45.2%    1710    48.0%   3812   46.4%
  11-20   249    5.3%     196     5.5%    445    5.4%
  21-30   279    6.0%     281     7.9%    560    6.8%
  31-40   519    11.1%    397     11.1%   916    11.2%
  41-50   492    10.6%    299     8.4%    791    9.6%
  51-60   382    8.2%     239     6.7%    621    7.6%
  61-70   321    6.9%     151     4.2%    472    5.7%
  71-80   212    4.6%     107     3.0%    319    3.9%
  81-90   99     2.1%     181     5.1%    280    3.4%
  Total   4655   100%     3561    100%    8216   100%

###### 

Characteristic of the subjects in Survey 2

  Age     Male   Female   Total                  
  ------- ------ -------- ------- ------- ------ --------
  0-10    2439   45.5%    2252    55.8%   4691   50.5%
  11-20   812    15.2%    539     13.4%   1351   14.5%
  21-30   216    4.2%     175     4.2%    391    4.2%
  31-40   426    8.1%     269     6.6%    695    7.5%
  41-50   535    9.9%     249     6.2%    784    8.4%
  51-60   361    6.7%     208     5.1%    569    6.1%
  61-70   297    5.5%     154     3.8%    451    4.9%
  71-80   201    3.8%     132     3.2%    333    3.6%
  81-90   14     0.2%     7       0.1%    21     0.2%
  Total   5301   100%     3985    100%    9286   100.0%

The cough was reported to be productive in 6256 of 8216 patients (76%) with complaint of wheeze 59%, breathlessness 22%, chest pain 9% and fever 18% in Survey 1, while cough (74%), wheeze (74%), breathlessness (26%), chest pain (13%) and fever (15%) were noticed in Survey 2. Of 8216 patients in Survey 1, 1919 (23%) had hypersusceptibility and 1359 (17%) had a family history of hypersusceptibility. Of 9177 patients in Survey 2, 1444 (15%) had hypersusceptibility and 621 (6%) had a family history of hypersusceptibility. More than 50% of cases had a history of allergic rhinitis, asthma, allergic conjunctivitis or atopic dermatitis (Table [3](#T3){ref-type="table"}). Inclusion subjects were given a diagnosis, mainly including COPD and asthma. Table [4](#T4){ref-type="table"} described the details of diagnosis. Tubercular pleurisy, stomatitis, acute pharyngitis, hypertension of pulmonary artery or fewer were listed in the section of others.

###### 

History of diseases in subjects with cough

  Disease                   Survey 1   Survey 2          
  ------------------------- ---------- ---------- ------ -------
  Allergic rhinitis         1359       16.5%      1972   20.3%
  Asthma                    3202       39.0%      6236   64.2%
  Allergic conjunctivitis   88         1.1%       227    2.3%
  Atopic dermatitis         120        1.5%       104    1.1%

###### 

Diagnosis of inclusion subjects

  Diagnosis                   Survey 1   Survey 2          
  --------------------------- ---------- ---------- ------ ---------
  Influenza                   2          0.02%      1      0.01%
  Rhinitis                    28         0.34%      30     0.31%
  Bronchial hyperreactivity   19         0.23%      0      0.00%
  COPD & Asthma               90         1.10%      0      0.00%
  Chronic bronchitis          124        1.51%      105    1.08%
  Pneumonia                   290        3.53%      87     0.90%
  Allergic cough              334        4.07%      301    3.10%
  Asthmatoid bronchitis       341        4.15%      292    3.01%
  Common cold                 394        4.80%      31     0.32%
  Chronic cough               520        6.33%      249    2.56%
  Acute bronchitis            932        11.34%     1000   10.30%
  Asthma (except CVA)         1799       21.89%     4521   46.56%
  COPD                        1303       15.86%     1135   11.69%
  Cough variant asthma(CVA)   1723       20.97%     1563   16.10%
  others                      317        3.86%      400    4.08%
                                                           
  **Total**                   8216       100.00%    9711   100.00%

Patients were treated with Procaterol, of whom 1098 in Survey 1 and 1046 in Survey 2 also had a combination of drugs, including expectorant (Ambroxol, Bromhexine, Carbocisteine), methylxanthines (Aminophylline, Theophylline), antihistamines (Cetirizine, Ketotifen, Cyprohentadine, Loratadine, Chlorphenamine, Tranilast), leukotriene modifiers (Montelukast), beta2 agonists (Salbutamol), inhaled long-acting beta2 agonists, Sametrol/Fluticasone, Formoferol/Budesonide, anticholinergics (Ipratropine). Combined drugs also included cough syrup (e.g. graifenesin, methylephedrine, chlorphenamine syrup, dextromethorphan hydrobromide with chlorpheniramine maleate, or pseudoe phedrine hydiochloride solution), Asmeton, Chinese traditional medicine, inhaled steroids (e.g. budesonide, fluticasone, and beclomethasone dipropionate), systemic steroids (e.g. methylprednisolone, prednisone, and dexamethasone), anti-virus (Ribavirin), or antibiotics(e.g. macrocyclic lactone, quinolone, cephalosporin, benzylpenicillin, and others), as shown Table [5](#T5){ref-type="table"}.

###### 

Treatments of inclusion subjects

  Treatment                      Survey 1              Survey 2                   
  ------------------------------ --------------------- ---------- ------- ------- -------
  Expectorant                    194                   2.36%      1       0.01%   
  Methylxanthines                126                   1.53%      39      0.40%   
  Antihistamines                 197                   2.40%      48      0.49%   
  Leukotriene modifiers          104                   1.27%      151     1.55%   
  SABAS                          43                    0.52%      184     1.89%   
  LABA                           34                    0.41%      53      0.55%   
  Anticholinergics               36                    0.44%      2       0.02%   
  Combination Drugs              82                    1.00%      1       0.01%   
  Chinese traditional medicine   169                   2.06%      14      0.14%   
  Inhaled steroids               180                   2.19%      225     2.32%   
  Systemic Corticosteroids       45                    0.55%      22      0.23%   
  Anti-virus                     6                     0.07%      0       0.00%   
                                 Macrocyclic lactone   88         1.07%   5       0.05%
                                 Quinolone             51         0.62%   0       0.00%
  Antibiotics                    Cephalosporin         267        3.25%   243     2.50%
                                 Benzylpenicillin      45         0.55%   31      0.32%
                                 others                12         0.15%   72      0.74%
  Others drugs (unknown)         414                   5.04%      19      0.20%   

The daily cough diary showed a rapid and highly significant reduction in the cough score (Table [6](#T6){ref-type="table"} and Table [7](#T7){ref-type="table"}). Of them, 83% in Survey 1 and 92% in Survey 2 had no symptom during the daytime after 14 days of treatment, while 82% in Survey 1 and 94% in Survey 2 had no symptom during the night. There was a significant difference between before and after the treatments (p \< 0.05 or 0.01, respectively). No patient dropped out because of severe adverse events.

###### 

Daytime cough symptom assessment

  Days   Cases in survey 1   Cases in survey 2                                      
  ------ ------------------- ------------------- ------ ------ ------ ------ ------ ------
  0      34                  807                 3146   3926   12     182    2561   6463
  1      35                  701                 2978   3617   7      206    2475   5764
  2      87                  910                 3493   2903   69     557    3337   4568
  3      218                 1291                4075   1890   227    1016   4371   3156
  4      366                 1671                4495   846    145    1426   6034   673
  5      521                 2070                4326   413    309    2390   5394   173
  6      805                 2692                3682   183    633    3342   4229   65
  7      1151                3482                2896   76     1326   3777   3473   42
  8      1449                4035                1756   41     890    4810   1614   29
  9      1895                4250                1077   24     1438   5065   647    26
  10     2382                4199                605    13     2240   4401   251    20
  11     3166                3075                304    5      3058   3617   102    19
  12     4370                2655                123    7      4758   1859   48     19
  13     5280                1799                62     4      5056   966    33     19
  14     6083                1388                46     5      5540   704    33     19

###### 

Night cough symptom assessment

  Days   Cases in survey 1   Cases in survey 2                                      
  ------ ------------------- ------------------- ------ ------ ------ ------ ------ ------
  0      149                 819                 2939   3942   43     239    2471   6441
  1      80                  818                 2632   3756   39     272    2424   5690
  2      167                 944                 2967   3165   88     615    2830   4971
  3      318                 1190                3382   2349   236    1110   4274   3132
  4      466                 1512                3944   1310   171    1467   5455   1159
  5      640                 1800                4126   637    339    2198   5420   296
  6      895                 2223                3826   287    555    3124   4483   92
  7      1276                2780                3272   133    1379   3777   3423   39
  8      1513                3180                2373   68     978    4664   1747   23
  9      1809                3655                1605   28     1395   4759   1091   19
  10     2151                3944                936    14     2048   4518   392    15
  11     2704                3809                495    4      3096   3591   132    15
  12     3711                3077                214    1      4651   1983   48     17
  13     4778                2121                87     1      5030   998    28     17
  14     5903                1417                48     0      5716   531    24     18

Discussion
==========

Cough is an important defensive reflex of the respiratory tract to clean up and protect the upper airway, while also being the commonest symptom for which patients seek medical advice. Causes and outcomes of cough differ with age and its presentation and other related symptoms vary with time (e.g. seasonality) and habits (e.g. smoking, occupation, body weight, use of drug etc.). Children below 10 years may have more episodes of bronchiolitis and asthma, which is the reason why their prevalence is high among both surveys in the present, while the adults suffer more from pneumonia and other chronic conditions. One of the common causes is chronic upper airway cough syndrome, previously referred to as postnasal drip syndrome, secondary to rhinosinus diseases, common cold, asthma, gastroesophageal reflux disease, bronchitis (e.g. acute bronchitis, chronic bronchitis, acute exacerbation of chronic bronchitis, or nonasthmatic eosinophilic bronchitis), bronchiectasis, post infectious cough, or others \[[@B12]\]. Thus, it is unexpectedly challenging for clinicians to define the etiology and pathogenesis of coughs in addition to selecting the optimal treatment in primary care settings. According to our knowledge, the present study incorporates the largest population sample yet to study the clinical epidemiology of coughs, which in turn can provide an overall figure indicating personal feelings, signs and clinical indications of coughs in primary care settings.

Subjects recruited in the present study had daytime or night symptoms of cough and diagnoses of respiratory disease, of whom about half were children. The accompanied symptoms included expectoration, fever, chest pain, usually indicative of the respiratory infection, wheezing, and breathlessness, which was usually accompanied with COPD and asthma. The two common diseases were COPD and asthma including cough variant asthma. Breathlessness and cough may be the clinical indicators of COPD or asthma exacerbations \[[@B13]\], while acute bronchitis should not be diagnosed until the common cold, asthma, and an acute exacerbation of chronic bronchitis have been ruled out \[[@B14]\]. However, it was often over-diagnosed, leading to the abuse of antibiotics. About 10% of patients were diagnosed as acute bronchitis in the Surveys, which was a lower percentage than that of COPD and asthma. Nasal disease was an important risk factor of cough, especially of chronic cough. It would be more valuable for the therapeutic strategies to further distinguish acute and chronic cough, rhinitis and other nasal disease if the proportion was large enough.

Hypersusceptibility has been suggested as one of major challenging factors in cough. We found that more than half of the patients with cough had a history of allergic rhinitis, asthma, allergic conjunctivitis or atopic dermatitis. About 15% to 23% patients had hyper-susceptibility, while 6% to 17% had a family history of hyper-susceptibility. More patients had a history of asthma in Survey 2 (64%) than in Survey 1 (39%). Allergic rhinitis is a common cause of postnasal drip and coughs, with a high prevalence in patients with asthma \[[@B15]\]. Patients with allergic rhinitis should be identified and clarified in the future study, in order to evaluate the significance and difference of allergic diseases in cough.

Procaterol was used as the treatment of patients, although the symptom of acute cough was sometimes automatically cured \[[@B16]\]. Responses to the used treatment were rapid and efficient, evidenced by the fact that 83% and 92% of patients in Surveys 1 and 2, respectively, had no daytime symptoms and 82% and 94% had no night symptoms after 14 days of treatment. Although our data showed that Procaterol could improve the symptom of cough in patients with respiratory diseases, we do not know the exact effects of the drug as our study was not a randomized controlled trial. Antibiotics were hardly effective for chronic cough and acute cough caused by the common cold, acute bronchitis, asthma, mild exacerbations of chronic bronchitis related to smoking, or environmental irritants \[[@B17],[@B18]\]. However, the application of antibiotics could be beneficial for upper airway cough syndrome resulted from bacterial sinusitis, and infection in the lower respiratory tract (whooping cough), if given early. The prescription rate of antibiotics was about 4-6% in patients with cough, which was considered as acceptable according to the conditions of the patients studied. Inhaled steroids were used in about 2% of patients, while systemic corticosteroids in 0.6%.

However, a number of limitations in the present study should be improved in future studies. For example, such cross-sectional studies should be followed up longitudinally, results based on self-reports should be compared with clinical information, including physical examinations, imaging and biochemical analyses. More diagnoses should be included in the questionnaire form, including pneumonia, common cold, acute bronchitis, and chronic bronchitis, even though it may be difficult to confirm those diagnoses. More attention on etiology and pathogenesis of cough should be considered as well as further education on cough management should be delivered to physicians working in primary care settings.

Conclusion
==========

In conclusion, cough causes a high level of morbidity in the community, annually resulting in massive health economy consequences. Demography and symptomatology seem to be similar to that reported in specialist hospital centers, but successful and precise diagnosis and treatment of cough was not as satisfactory. Management of cough in primary care needs to be improved in China.
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